Pharmacokinetics and Pharmacodynamics Practice Questions

Q: What is the advantage of the sublingual route for drug administration?

It prevents or bypasses first-pass metabolism.. ### Explanation **Correct Option: A. It prevents or bypasses first-pass metabolism.** The sublingual route involves placing a drug under the tongue, where it dissolves and is absorbed directly through the oral mucosa into the systemic circulation via the **superior vena cava**. Unlike the oral route, the drug does not enter the portal circulation; therefore, it bypasses the liver (the primary site of first-pass metabolism). This ensures higher bioavailability and a rapid onset of action, making it ideal for emergencies like acute anginal attacks. **Analysis of Incorrect Options:** * **B. It is easy to administer:** While relatively simple, "ease of administration" is a subjective clinical convenience rather than a pharmacological advantage. The primary *pharmacokinetic* advantage is the bypass of hepatic metabolism. * **C. The drug must be lipid-soluble:** This is a **requirement** for the route to work, not an advantage. Only lipid-soluble, non-irritating drugs (e.g., Nitroglycerin, Buprenorphine) can diffuse across the lipid bilayer of the oral mucosa. * **D. It can be spit out if signs of toxicity appear:** While true that the drug can be removed to stop further absorption, this is a safety feature/precaution rather than the primary therapeutic advantage sought when choosing this route. **High-Yield Clinical Pearls for NEET-PG:** * **Nitroglycerin (GTN):** The classic example. It has very high first-pass metabolism (>90%), making the sublingual route essential for its efficacy in angina. * **Other Sublingual Drugs:** Buprenorphine (opioid), Desmopressin (analogue of ADH), and Nifedipine (though no longer preferred for hypertensive emergencies due to unpredictable BP drops). * **Key Concept:** Any drug absorbed from the mouth, pharynx, or rectum (partially) bypasses the liver, avoiding the "First-Pass Effect."

Q: Which of the following drugs is not converted into an active metabolite?

Lisinopril. **Explanation:** The question tests the concept of **Prodrugs** and **Active Metabolites**. Most drugs are inactivated by metabolism, but some are converted into active forms to exert their therapeutic effects. **Why Lisinopril is the Correct Answer:** Lisinopril is a notable exception among ACE inhibitors. While most ACE inhibitors (like Enalapril, Ramipril, and Perindopril) are **prodrugs** that must be converted by the liver into their active "-at" forms (e.g., Enalaprilat), **Lisinopril and Captopril are already active drugs**. They do not undergo hepatic activation and are excreted unchanged by the kidneys. This makes Lisinopril a preferred choice in patients with hepatic impairment. **Analysis of Incorrect Options:** * **Cyclophosphamide:** This is a classic **prodrug**. It is inactive in vitro and must be activated by hepatic cytochrome P450 enzymes into **4-hydroxycyclophosphamide** and **aldophosphamide** to exert its cytotoxic effect. * **Diazepam:** This benzodiazepine has a very long half-life because it is converted into several **active metabolites**, including **nordiazepam** (desmethyldiazepam) and **oxazepam**, which prolong its sedative effects. * **Fluoxetine:** This SSRI is metabolized into **norfluoxetine**, an active metabolite with an even longer half-life (7–15 days) than the parent drug, contributing to its sustained clinical effect. **NEET-PG High-Yield Pearls:** * **ACE Inhibitor Rule:** All ACE inhibitors are prodrugs **EXCEPT** Captopril and Lisinopril. * **Active Metabolite of Morphine:** Morphine-6-glucuronide (more potent than morphine). * **Prodrug of Epinephrine:** Dipivefrine (used in glaucoma). * **Prodrug of Dopamine:** Levodopa (crosses the blood-brain barrier).

Q: What is Hoffmann's elimination?

Inactivation of a drug by molecular rearrangement.. ### **Explanation** **Hoffmann's elimination** is a unique pharmacokinetic process where a drug undergoes spontaneous non-enzymatic degradation in the plasma and tissues. **1. Why Option D is Correct:** The correct answer is **inactivation of a drug by molecular rearrangement**. Unlike most drugs that require hepatic enzymes or renal clearance, drugs undergoing Hoffmann's elimination break down spontaneously due to the physiological pH and temperature of the body. This is a purely chemical process (molecular rearrangement) that does not involve any biological catalysts (enzymes). **2. Why Other Options are Incorrect:** * **Option A:** This refers to **biotransformation** (metabolism), typically occurring in the liver via Cytochrome P450 enzymes. * **Option B:** This refers to **renal excretion**, the primary route for water-soluble drugs. * **Option C:** This refers to **biliary or fecal excretion**, common for large molecular weight compounds or unabsorbed oral drugs. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Prototype Drug:** The classic example is **Atracurium** (a non-depolarizing neuromuscular blocker). Its derivative, **Cisatracurium**, also undergoes this process. * **Clinical Advantage:** Because it does not rely on the liver or kidneys, Atracurium is the **muscle relaxant of choice for patients with liver or kidney failure**. * **Factors Affecting Rate:** Since it is a chemical reaction, the rate of Hoffmann's elimination is increased by **hyperthermia** and **alkalosis**, and decreased by hypothermia and acidosis. * **Metabolite Note:** A byproduct of this reaction is **laudanosine**, which can cross the blood-brain barrier and potentially cause seizures in very high concentrations (though rare clinically).

Q: After three half-lives, what percentage of an original drug dose remains in the body?

12.50%. **Explanation** The concept of **Half-life ($t_{1/2}$)** refers to the time required for the plasma concentration of a drug to decrease by 50%. This follows **First-order kinetics**, where a constant fraction of the drug is eliminated per unit of time. To calculate the remaining percentage after multiple half-lives, we use the formula: **Remaining Amount = $100 \times (1/2)^n$** (where $n$ is the number of half-lives). * **Initial dose:** 100% * **After 1st half-life:** 50% remains * **After 2nd half-life:** 25% remains (50% of 50) * **After 3rd half-life:** **12.5% remains** (50% of 25) **Analysis of Options:** * **A (12.50%): Correct.** As calculated above, three half-lives reduce the drug concentration to one-eighth of the original dose. * **B (87.50%):** This represents the amount of drug **eliminated** after three half-lives (100% - 12.5%), not the amount remaining. * **C (75%):** This is the amount eliminated after two half-lives. * **D (94%):** This is the approximate amount eliminated after four half-lives (93.75%). **NEET-PG High-Yield Pearls:** 1. **Steady State:** It takes approximately **4 to 5 half-lives** for a drug to reach steady-state concentration ($C_{ss}$) during constant administration. 2. **Complete Elimination:** A drug is considered clinically "cleared" from the body after **5 half-lives** (97% eliminated). 3. **Zero-order Kinetics:** Unlike first-order, a constant *amount* (not fraction) is eliminated per unit time (e.g., Alcohol, Phenytoin, Aspirin at high doses). Here, half-life is not constant.

Q: If a drug has a Volume of Distribution (Vd) equal to 60L, what does this indicate about the drug's distribution?

The drug is significantly sequestered in tissue sites.. **Explanation:** The **Volume of Distribution (Vd)** is a theoretical volume that relates the total amount of drug in the body to its concentration in the plasma ($Vd = \text{Total amount of drug} / \text{Plasma concentration}$) [1]. In an average 70 kg adult, the total body water is approximately **42 liters** [1]. * **Plasma volume:** ~3-4 L [1] * **Extracellular fluid:** ~14 L [1] * **Total body water:** ~42 L [1] If a drug has a **Vd of 60L**, it exceeds the total body water (42L). This indicates that the drug is not confined to the plasma or extracellular fluid but has distributed extensively into the tissues [1]. A high Vd suggests the drug is **lipid-soluble** and is being **sequestered in tissue sites** (like fat, muscle, or specific organs), resulting in a very low plasma concentration [1]. **Analysis of Incorrect Options:** * **Option B:** High plasma protein binding keeps the drug confined to the vascular compartment, resulting in a **low Vd** (e.g., Warfarin, Vd ≈ 8L) [1]. * **Option C:** Vd relates to distribution, not directly to the rate of excretion. However, drugs with a high Vd are often harder to remove via hemodialysis because they are hidden in tissues rather than circulating in the blood. **NEET-PG High-Yield Pearls:** 1. **Low Vd ( 42L):** Drug is sequestered in tissues (e.g., Digoxin, Chloroquine) [1]. **Chloroquine** has a massive Vd (~13,000L) due to high tissue binding [1]. 3. **Loading Dose Calculation:** $LD = Vd \times \text{Target Plasma Concentration}$. Drugs with high Vd require a higher loading dose to achieve therapeutic levels.

Q: Which of the following drugs is NOT metabolized by acetylation?

Metoclopramide. The correct answer is **Metoclopramide**. **Metoclopramide** is primarily metabolized in the liver via **glucuronidation and sulfation**, not acetylation. It is a dopamine D2 receptor antagonist used as a prokinetic and antiemetic. **Acetylation** is a Phase II metabolic reaction catalyzed by the enzyme **N-acetyltransferase (NAT)**. Drugs metabolized by this pathway are subject to genetic polymorphism, dividing the population into "Fast Acetylators" and "Slow Acetylators." **Why the other options are incorrect:** * **Isoniazid (INH):** The classic example of an acetylated drug. Slow acetylators are at a higher risk of peripheral neuropathy, while fast acetylators may develop hepatotoxicity. * **Dapsone:** Used in leprosy; it is metabolized by acetylation. Slow acetylators are more prone to hematological side effects like methemoglobinemia. * **Hydralazine:** An antihypertensive that undergoes significant first-pass metabolism via acetylation. **High-Yield Clinical Pearls for NEET-PG:** To remember the drugs metabolized by acetylation, use the mnemonic **"SHIP"**: * **S** – Sulfonamides (e.g., Sulfasalazine, Dapsone) * **H** – Hydralazine * **I** – Isoniazid * **P** – Procainamide **Key Concept:** Slow acetylators are at an increased risk of **Drug-Induced Lupus Erythematosus (DILE)**, particularly when taking Hydralazine or Procainamide. Metoclopramide does not cause this because it bypasses the acetylation pathway.

Question 1

What is the advantage of the sublingual route for drug administration?

Accepted Answer

It prevents or bypasses first-pass metabolism.

Answer

It is easy to administer.

Answer

The drug must be lipid-soluble.

Answer

It can be spit out if signs of toxicity appear.

Question 2

Which of the following drugs exhibit zero-order kinetics at high doses?

Accepted Answer

Phenytoin and Propranolol

Answer

Digoxin and Propranolol

Answer

Amiloride and Probenecid

Answer

Lithium and Theophylline

Question 3

Which of the following drugs is not converted into an active metabolite?

Accepted Answer

Lisinopril

Answer

Cyclophosphamide

Answer

Diazepam

Answer

Fluoxetine

Question 4

Which one of the following drugs does not undergo the first-pass effect?

Accepted Answer

Insulin

Answer

Propranolol

Answer

Lidocaine

Answer

Morphine

Question 5

What is Hoffmann's elimination?

Accepted Answer

Inactivation of a drug by molecular rearrangement.

Answer

Inactivation of a drug by a metabolizing enzyme.

Answer

Unchanged excretion of a drug by the kidney.

Answer

Excretion of a drug in the feces.

Question 6

After three half-lives, what percentage of an original drug dose remains in the body?

Accepted Answer

12.50%

Answer

87.50%

Answer

75%

Answer

94%

Question 7

If a drug has a Volume of Distribution (Vd) equal to 60L, what does this indicate about the drug's distribution?

Accepted Answer

The drug is significantly sequestered in tissue sites.

Answer

The drug is highly bound to plasma proteins.

Answer

The drug is easily excreted.

Answer

None of the above.

Question 8

A clinical pharmacologist is gathering pharmacokinetic data during clinical trials of a new antimicrobial agent. He has already determined that the half-life of this drug is 4 hours. He began a continuous intravenous drip 24 hours ago at a rate of 10 mg/min. Blood tests after 24 hours reveal that the patient's drug plasma concentration is 20 mg/L. What is the clearance of this agent?

Accepted Answer

0.5 L/min

Answer

2 L/min

Answer

10 L/min

Answer

50 L/min

Question 9

Which of the following drugs is NOT metabolized by acetylation?

Accepted Answer

Metoclopramide

Answer

Isoniazid

Answer

Dapsone

Answer

Hydralazine

Question 10

Which of the following is NOT a metabotropic receptor?

Accepted Answer

Beta receptor for norepinephrine

Answer

GABA receptor

Answer

Acetylcholine receptor

Answer

Alpha receptor for norepinephrine

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?